Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

Table 3 Summary of the clonoSEQ Assay precision

		%CV attributed to each variable at cell inputs^a
Lot-to-lot variability	Number of input cancer cells	2.14	6.13	21.44	61.26	214.4	612.56
	Instrument set (%)	0	1	0	1	1	1
	Operator (%)	2	0	1	2	0	0
	Processing day (%)	0	0	1	1	0	3
	Processing run (%)	0	0	1	0	0	0
	Reagent lot (%)	0	0	0	1	2	1
	Residual variability (%)	68	49	28	23	19	18
	Total MRD measurements, n	3456	3456	3564	3960	3960	3828

%CV percent coefficient of variance, ALL acute lymphoblastic leukemia, CLL chronic lymphocytic leukemia, MM multiple myeloma
^aThese values were aggregated across diseases (ALL, CLL, and MM) and total DNA input levels

ISSN: 1471-2407